Sequential use of biologics
Data from a Danish database show that, of 1422 patients with PsA starting on anti-TNF therapy, 548 patients (39%) switched to a second biologic agent during up to ten years of follow up.37
Combined data from prospective cohorts of national databases will provide further insight in switching biologics.38 l
*Data on efalizumab and alefacept are not presented, due to the fact that these drugs are no longer available or prescribed in patients with psoriasis.
Please note that this chapter was written in mid-2013 and only minimally updated prior to publication. Not all subsequent publications and data could be taken into account.
References 1. Smith CH, Ormerod AD (Chair of Guideline Group) et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987–1019.
2. Dutch Guideline Psoriasis 2011; www.huidarts.info/
3. Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137–74.
4. Gossec L et al. European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71(1):4–12.
5. Glintborg B et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor a therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382–90.
6. de Vries ACQ et al. Interventions for nail psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD007633. DOI: 10.1002/14651858. CD007633.pub2.
7. Rich P et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol 2013;doi: 10.1111/ bjd.12632. [Epub ahead of print].
8. Trial registry: NTR1559. Available from: http://www. trialregister.nl/trialreg/admin/rctview.asp?TC=1559
. Accessed January 2014.
9. de Groot M et al. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 2006;155:808–14.
10. NICE TA180 guideline: Ustekinumab for the treatment of adults with moderate to severe psoriasis. www.nice.org.uk/nicemedia/pdf/
30 11. Samarasekera E et al. Assessment and www.hospitalpharmacyeurope.com
management of psoriasis: summary of NICE guidance. BMJ 2012;345:e6712.
12. Papp KA et al. PHOENIX 1 Investigators. PHOENIX 2 Investigators; ACCEPT Investigators. Long-term safety of ustekinumab in patients with moderate- to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168:844–54.
13. Nast A et al. Which Antipsoriatic Drug Has the Fastest Onset of Action?-Systematic Review on the Rapidity of the Onset of Action. J Invest Dermatol 2013; doi: 10.1038/jid.2013.78. [Epub ahead of print].
14. Nijsten T et al. The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab’s withdrawal. Arch Dermatol 2009;145:1037–9.
15. Paller AS et al. Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241–51.
16. EMA Assessment report for Enbrel. www.ema. europa.eu/docs/en_GB/document_library/
17. Pathirana D et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol 2009;23:1–70.
18. Bae YS et al. National Psoriasis Foundation. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012;67:459–77.
19. Tsai TF et al. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol 2013;168(2):444–6.
20. Gottlieb AB et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012;167:649–57.
21. Zachariae C et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008;88:495–501.
22. Park KK, Wu JJ, Koo J. A randomized, ‘head-to- head’ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol 2012; 27:899–906.
23. Wolf P et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. Br J Dermatol 2012;166:147–53.
24. Gisondi P et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator- blinded pilot trial. Br J Dermatol 2008;158:1345–9.
25. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab,
etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164:1091–6.
26. Lucka TC et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012;26:1331–44.
27. Ferrándiz C et al. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2012;26:768–77.
28. Ahn CS et al. Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. Am J Clin Dermatol 2013;14(4):315–26.
29. Umar N et al. Matching physicians’ treatment recommendations to patients’ treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol 2013;27:763–70.
30. Lecluse LL et al. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol 2009;160:1340–3.
31. Mrowietz U et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to- severe plaque psoriasis. J Eur Acad Dermatol Venereol 2013; doi: 10.1111/jdv.12118. [Epub ahead of print].
32. Lecluse LL et aI. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 2009;161:948–51.
33. Van Lümig PP et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010;163:838–46.
34. Clemmensen A et al. Responses to ustekinumab in the anti TNF agent-naïve vs. anti-TNF agent- exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011;25:1037–40.
35. Strober BE et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol 2011;64:671–81.
36. Vender R. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. J Drugs Dermatol 2011;10:396–402.
37. Glintborg B et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor a inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013;65:1213–23.
38. Garcia-Doval I et al. The Psonet Network. Systemic psoriasis therapy shows high between-countries variation. A sign of unwarranted variation? Cross-sectional analysis of baseline data from the
Psonet registries. Br J Dermatol 2013;169(3):710–4. No: PHEM/IMM/0613/0002g
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40